Lithium Ion

Lithium Ion

SCHEMBL1004513

CCN(CC)c1nc2c(C(=O)[O-])cccc2o1.[Li+]

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 4/20 0.54
ELANE P08246 5/20 0.42
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
TOP2A P11388 2/20 0.35
CMKLR1 Q99788 3/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
PARP1 P09874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL1004907 0.88 HTR3A (0.46) HTR3AALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL1004514 0.86 HTR3A (0.54) HTR3AELANEALDH1A1HPGDHSD17B10
Lithium Ion SCHEMBL1003559 0.80 HTR3A (0.55) HTR3APPARGPPARDPPARATOP2A
SCHEMBL27755483 0.77 HTR3A (0.47) HTR3AELANEALDH1A1HPGDHSD17B10
SCHEMBL24163185 0.74 HTR3A (0.48) HTR3AALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL1004908 0.74 HTR3A (0.46) HTR3AALDH1A1SMN1; SMN2TOP2ACMKLR1
SCHEMBL1006366 0.72 HTR3A (0.66) HTR3A
SCHEMBL1005843 0.72 TOP2A (0.51) HTR3AALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL1005419 0.71 HTR3A (0.53) HTR3AALDH1A1SMN1; SMN2TOP2ACMKLR1
SCHEMBL3991136 0.70 HTR3A (0.52) HTR3AALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863271-B2 2-aminobenzoxazole carboxamides as 5HT3 modulators ALBANY MOLECULAR RESEARCH, INC. (US) 2011-01-04 US disclosed
EP-2061460-A2 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS Albany Molecular Research, Inc. (US) 2009-05-27 EP disclosed
US-20080255114-A1 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS AMR TECHNOLOGY, INC. (US) 2008-10-16 US disclosed
WO-2008019372-A2 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS ALBANY MOLECULAR RESEARCH, INC. (US) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255114-A1 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS HTR3E, HTR3C, HTR3A HTR3A 3/4885ELANE 4093/4885ALDH1A1 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.